Clovis Oncology Announces First Patient Enrolled in the Phase 2 Portion of the LIO-1 Trial Evaluating the Combination of Lucitanib and Opdivo in Gynecologic Cancers
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today treatment of the first patient in the Phase 2 portion of the LIO-1 trial evaluating the combination of lucitanib, Clovis’ investigational angiogenesis inhibitor, including vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3), and Opdivo® (nivolumab), Bristol Myers Squibb’s PD-1 inhibitor, for the treatment of gynecologic cancers. The LIO-1 trial is sponsored by Clovis as part of its broad clinical collaboration with Bristol Myers Squibb.
“The Phase 2 part of the LIO-1 trial will advance our scientific understanding of the potential for an inhibitor of multiple tyrosine kinases, including VEGF, such as lucitanib, to be combined with a PD-1 inhibitor for the treatment of gynecologic cancers,” said Dr. Erika Hamilton, Director of the Breast and Gynecologic Research Program, Sarah Cannon Research Institute at Tennessee Oncology. “It is estimated that nearly 100,000 women will be diagnosed with a gynecologic cancer in the U.S. this year alone, and it is vital that we identify new treatment options, in particular new combinations, for these women.”
The Phase 2 part of LIO-1 is an open-label study to evaluate the safety and efficacy of lucitanib and Opdivo in patients with advanced gynecological solid tumors, including a broad spectrum of ovarian and endometrial subtypes including clear cell disease and patients with cervical cancer. The primary endpoint is confirmed best overall response rate based on investigator assessment according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. The study will be conducted in the U.S. and Europe, in collaboration with the European Network for Gynaecological Oncological Trial groups (ENGOT) for European study sites.
The Phase 2 dosing regimen for the LIO-1 study is based on results from the recently completed Phase 1b dose-escalation portion of the LIO-1 study. Abstracts describing the initial results of the Phase 1b portion of the LIO-1 study, as well as a trials-in-progress description of the Phase 2 study design of LIO-1, have been accepted as ePosters at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 in September.
“The initiation of the Phase 2 stage of the LIO-1 clinical trial is an important milestone for the lucitanib development program, and I am grateful to our team and our investigators for their commitment to initiating this study safely and expeditiously in this new COVID-19 era,” said Patrick J. Mahaffy, President and Chief Executive Officer of Clovis Oncology. “Importantly, we look forward to sharing initial Phase 1b data from LIO-1 at the upcoming virtual ESMO Congress, as well as data for each of our commercial and development-stage products. We are committed to pursue innovative clinical studies, both monotherapy and in combination, that are supported by a strong scientific rationale and offer the potential to provide additional treatment options with meaningful clinical benefit to a broad group of cancer patients.”
More information about the LIO-1 trial (NCT04042116) is available here.
Lucitanib is an oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3), platelet-derived growth factor receptors alpha and beta (PDFGRα/β) and fibroblast growth factor receptors 1 through 3 (FGFR1-3). Emerging clinical data support the combination of angiogenesis inhibitors and immunotherapy to increase effectiveness in multiple cancer indications. Angiogenic factors, such as vascular endothelial growth factor (VEGF), are frequently up-regulated in tumors and create an immunosuppressive tumor microenvironment. Use of antiangiogenic drugs may reverse this immunosuppression and augment response to immunotherapy.
Lucitanib is an unlicensed medical product.
About Clovis Oncology
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops, with partners, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado; please visit www.clovisoncology.com for more information, including additional office locations in the U.S. and Europe.
Clovis Oncology Forward-Looking Statement
To the extent that statements contained in this press release are not descriptions of historical facts regarding Clovis Oncology, they are forward-looking statements reflecting the current beliefs and expectations of management. Examples of forward-looking statements contained in this press release include, among others, statements regarding the potential benefit of our drug candidate lucitanib in combination with nivolumab and expanding treatment options for a broader set of patient populations. Such forward-looking statements involve substantial risks and uncertainties that could cause our future results, performance or achievements to differ significantly from that expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, whether future pre-clinical or clinical study results will support continued development or regulatory approval, whether our clinical development programs for our drug candidates and those of our partners can be completed on time or at all, whether future study results will be consistent with study findings to date, and actions by the FDA, the EMA or other regulatory authorities regarding data required to support drug applications and whether to accept or approve drug applications that may be filed, as well as their decisions regarding drug labeling, reimbursement and pricing, and other matters that could affect the development, approval, availability or commercial potential of our drug candidates. Clovis Oncology does not undertake to update or revise any forward-looking statements. A further description of risks and uncertainties can be found in Clovis Oncology's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its reports on Form 10-Q and Form 8-K.
Clovis Media Contacts:
Lisa Guiterman, 301.217.9353
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Workiva Wraps Up Amplify 2020: Global Conference Transformed into a Virtual Experience for Over 6,000 Attendees Across 60 Countries22.9.2020 19:13:00 EEST | Press release
Workiva Inc. (NYSE:WK), the company that simplifies complex work, wrapped up its largest annual conference, Workiva Amplify, following three days of incredible virtual experiences. More than 6,000 attendees from over 60 countries participated in 42 customer, partner and Workiva led sessions focused on solving the universal challenges of data, process and reporting complexity. “This year’s record attendance at Amplify underscores the importance that organizations have placed on utilizing cloud platforms to enable greater transparency, instill trust and streamline processes,” said Workiva CEO Marty Vanderploeg. “We are proud that Amplify continues to be a place where our customers can access innovative technology and insights that help them confidently move their organizations forward.” Workiva Amplify 2020 Highlights include: Trust in an Age of Transformation The Amplify general session featured Workiva leadership and customers who highlighted the need for stability and experience when
OCP Announces Date of Second Quarter and First Half 2020 Earnings22.9.2020 19:10:00 EEST | Press release
OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its second quarter and first half 2020 results on Tuesday, September 29, 2020. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 9:00 a.m. EDT, 2:00 p.m. Morocco and London time (GMT+1). OCP senior management will host a conference call to discuss second quarter and first half 2020 results at 10:00 a.m. EDT, 3:00 p.m. Morocco and London time (GMT+1) on Tuesday, September 29, 2020 for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing firstname.lastname@example.org. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century’s production history. OCP has exc
Movius WhatsApp Integration Creates First True Compliant Mobile Unified Communications Solution22.9.2020 18:00:00 EEST | Press release
Movius, the leading global provider of mobile unified communication software, is now enabling enterprises to securely and compliantly communicate with clients on their preferred mobile messaging channel. Today, the company announced the integration of WhatsApp support from within Movius MultiLine, their secure mobile communication service that can be deployed over any smartphone device on any global carrier. The integration will help unify and capture all business voice and messaging channels through a single integrated user experience, while enabling firms to effortlessly meet regulatory and surveillance needs. An open Beta for this integration is available now and general availability is expected in the fourth quarter, 2020. As users continue to work remotely, they will find the expanded enterprise service provides unmatched productivity anywhere – and compliance everywhere – especially as companies accelerate their emerging Bring Your Own Device (BYOD) strategies and implementations
Bioventus Reaches Milestone with 2 Million DUROLANE® Treatments Worldwide22.9.2020 17:30:00 EEST | Press release
Bioventus, a global leader in Innovations For Active Healing, is celebrating a milestone and recognizing more than 2 million treatments worldwide with DUROLANE, its single-injection, hyaluronic acid (HA) product used in the treatment of pain associated with osteoarthritis (OA). DUROLANE is the original single injection hyaluronic acid therapy, has helped patients in nearly 30 countries and is a trusted therapy for clinicians in the management of OA. Proven safe and effective, DUROLANE has more clinical studies than any other US single-injection HA, and has also been proven to provide greater reduction in OA knee pain versus Synvisc-One®.1,2 It has longer lasting pain relief versus a steroid injection, is safe and repeated use of DUROLANE does not increase the incidence of adverse events.3,4 DUROLANE is available in its original 3ml syringe for treatment of large joints and in a 1ml syringe, known as DUROLANE SJ, to enable treatment of small joints.* Both are produced using a natural, s
Andersen Global Expands Presence in Northern Africa22.9.2020 16:30:00 EEST | Press release
Further demonstrating its commitment to expanding its global platform in Africa, Andersen Global announced it entered the Algerian market by way of a Collaboration Agreement with full-service tax firm Cabinet Hadj Ali. The Algiers-based firm, led by Managing Director Samir Hadjali, was founded nearly 60 years ago and has grown to include more than 40 professionals. The firm offers tax and advisory services to owner-managed businesses, large multinational companies and subsidiaries of international corporations in a wide variety of industries. “Our firm was previously an Arthur Andersen affiliate, so we appreciate and understand the importance and impact of working with like-minded individuals around the globe with whom we share a commitment to stewardship, transparency and providing seamless service internationally,” Samir said. “Since 1962, our firm has prided itself on providing premier client service in this unique market, and we’re going to take it further now, broadening our servi
causaLens launches the first causal AI platform22.9.2020 16:00:00 EEST | Press release
causaLens , a deep-tech company predicting and optimising the global economy, has released the World’s first causal Artificial Intelligence (causal AI) enterprise platform. Businesses no longer have to rely on curve-fitting machine learning platforms unable to handle the complexity of today's world. They are invited to join the real AI revolution with a platform that understands cause and effect. The causaLens platform defines a new category of machine intelligence. Its next generation AI engine harnesses an understanding of cause and effect relationships to directly optimise business KPIs. “Businesses investing in the current form of machine learning (ML), including AutoML, have just been paying to automate a process that fits curves to data without an understanding of the real world. They are effectively driving forward by looking in the rear-view mirror,” explains causaLens CEO Darko Matovski. “Our platform takes a radically different approach. Causal AI teaches machines to understa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom